Thrombopoietin, Recombinant, Mouse (TPO, Mpl-ligand, MGDF)

Recombinant Murine TPO is a single, non-glycosylated soluble polypeptide chain containing 174 amino acids and having a molecular mass of 18.7kD which comprises the receptor binding domain of the Mpl-ligand protein.\n\nSequence :\nThe sequence of the first five N-terminal amino acids was determined and was found to be Ser-Pro-Val-Ala-Pro.\n\nBiological Activity:\nRecombinant TPO is fully biologically active when compared to standard. The ED50 as determined by the dose-dependent stimulation of MO7e cells is less then 1 ng/ml, corresponding to a Specific Activity of 1x10e6 IU/mg.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Reconstitute to nominal volume by adding sterile ddH2O, 0.1% HSA or BSA. Aliquot and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

T5050-12

Size

2ug

Form

Supplied as a lyophilized powder. No additives. Reconstitute with sterile ddH2O, 0.1% HSA or BSA to a concentration of (same/more than)100ug/ml, which can then be further diluted to other aqueous solutions.

Purity

(same/more than) 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.

References

1. Thrombopoietin induces HOXA9 nuclear transport in immature hematopoietic cells: potential mechanism by which the hormone favorably affects hematopoietic stem cells. Kirito K, Fox N, Mol Cell Biol 2004 Aug;24(15):6751-62 2. Synergistic effects on erythropoiesis, thrombopoiesis, and stem cell competitiveness in mice deficient in thrombopoietin and steel factor receptors. Antonchuk J, Hyland CD, Alexander WS, Blood 2004 Sep 1;104(5):1306-13 3. A functional erythropoietin receptor is necessary for the action of thrombopoietin on erythroid cells lacking c-mpl. Rouleau C, Cui K, Exp Hematol 2004 Feb;32(2):140-8 4. Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Carpinelli MR, Hilton DJ, Antonchuk JL, Hilton AA, Proc Natl Acad Sci U S A 2004 Apr 27;101(17):6553-8 5. Hematopoietic-repopulating defects from STAT5-deficient bone marrow are not fully accounted for by loss of thrombopoietin responsiveness. Bradley HL, Couldrey C, Blood 2004 Apr 15;103(8):2965-72 6. Induction of megakaryocytopoiesis and thrombocytopoiesis by JTZ-132, a novel small molecule with thrombopoietin mimetic activities. Inagaki K, Oda T, Shinkai H, Blood 2004 Jul 1;104(1):58-64.